• Ahmed K Pasha, Charlene Y Clements, Charity A Reynolds, Maegan K Lopez, Ciara A Lugo, Yulisa Gonzalez, Farshad M Shirazi, and Aiden Abidov.
• Hospital Internal Medicine, Mayo Clinic Health System, Mankato, Minn.
• Am. J. Med. 2021 Feb 1; 134 (2): 182-193.

AbstractUtilization of marijuana as a medicinal agent is becoming increasingly popular, and so far, 25 states have legalized it for medical purposes. However, there is emerging evidence that marijuana use can result in cardiovascular side effects, such as rhythm abnormalities, syncope/dizziness, and myocardial infarction, among others. Further, there are currently no stringent national standards or approval processes, like Food and Drug Administration (FDA) evaluation, in place to assess medical marijuana products. This review includes the largest up-to-date pooled population of patients with exposure to marijuana and reported cardiovascular effects. Although purported as benign by many seeking to advance the use of marijuana as an adjunctive medical therapy across the country, marijuana is associated with its own set of cardiovascular risks and deserves further definitive study and the same level of scrutiny we apply in research of all other types of medications. When used as a medicinal agent, marijuana should be regarded accordingly, and both clinical providers and patients must be aware of potential adverse effects associated with its use for early recognition and management.Copyright © 2020 Elsevier Inc. All rights reserved.

10 keywords...

hide…